1151 related articles for article (PubMed ID: 28941764)
21. Adherence to Kidney Disease: Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters.
Roetker NS; Peng Y; Ashfaq A; Gilbertson DT; Wetmore JB
Am J Nephrol; 2019; 49(3):225-232. PubMed ID: 30820015
[TBL] [Abstract][Full Text] [Related]
22. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).
Manns BJ; Hodsman A; Zimmerman DL; Mendelssohn DC; Soroka SD; Chan C; Jindal K; Klarenbach S
Am J Kidney Dis; 2010 May; 55(5):800-12. PubMed ID: 20438984
[No Abstract] [Full Text] [Related]
23. KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD.
Drawz PE; Beddhu S; Bignall ONR; Cohen JB; Flynn JT; Ku E; Rahman M; Thomas G; Weir MR; Whelton PK
Am J Kidney Dis; 2022 Mar; 79(3):311-327. PubMed ID: 35063302
[TBL] [Abstract][Full Text] [Related]
24. [Changes in mineral and bone disorder management in a French cohort of hemodialysis patients between 2008 and 2012: The National Bone and Mineral Metabolism observatory (Photo-Graphe 2 and 3)].
Pelletier S; Roth H; Bouchet JL; Drueke TB; Hannedouche T; Jean G; London G; Fouque D;
Nephrol Ther; 2016 Jun; 12(3):171-7. PubMed ID: 26822333
[TBL] [Abstract][Full Text] [Related]
25. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
[TBL] [Abstract][Full Text] [Related]
26. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
27. Indian commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorders.
Jha V; Kher V; Pisharody R; Sharma RK; Abraham G; Gokulnath ; Almeida A; Gupta A
Indian J Nephrol; 2011 Jul; 21(3):143-51. PubMed ID: 21886971
[TBL] [Abstract][Full Text] [Related]
28. [The expanding concept of CKD-MBD].
Komaba H
Clin Calcium; 2016 Sep; 26(9):1253-60. PubMed ID: 27561339
[TBL] [Abstract][Full Text] [Related]
29. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).
Moe S; Drüeke T; Cunningham J; Goodman W; Martin K; Olgaard K; Ott S; Sprague S; Lameire N; Eknoyan G;
Kidney Int; 2006 Jun; 69(11):1945-53. PubMed ID: 16641930
[TBL] [Abstract][Full Text] [Related]
30. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C.
Roth D; Bloom RD; Molnar MZ; Reese PP; Sawinski D; Sise ME; Terrault NA
Am J Kidney Dis; 2020 May; 75(5):665-683. PubMed ID: 32279907
[TBL] [Abstract][Full Text] [Related]
31. Chronic kidney disease-mineral-bone disorder: a new paradigm.
Moe SM; Drüeke T; Lameire N; Eknoyan G
Adv Chronic Kidney Dis; 2007 Jan; 14(1):3-12. PubMed ID: 17200038
[TBL] [Abstract][Full Text] [Related]
32. [Disorders of bone and mineral metabolism in CKD: CKD-MBD as a new entity].
Tsukamoto Y
Clin Calcium; 2007 May; 17(5):660-4. PubMed ID: 17470993
[TBL] [Abstract][Full Text] [Related]
33. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
[TBL] [Abstract][Full Text] [Related]
34. [Update 2017 of the KDIGO guidelines on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). What are the real changes?].
Pasquali M; Bellasi A; Cianciolo G; Massimetti C; Mereu MC; Morrone L; Panuccio V;
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786179
[TBL] [Abstract][Full Text] [Related]
35. [Chronic kidney disease (CKD) and bone. From renal osteodystrophy to CKD-MBD: new disease entity].
Tsukamoto Y
Clin Calcium; 2009 Apr; 19(4):479-84. PubMed ID: 19329825
[TBL] [Abstract][Full Text] [Related]
36. [Kidney and bone update : the 5-year history and future of CKD-MBD. The changes after the introduction of CKD-MBD as a new entity].
Koizumi M; Fukagawa M
Clin Calcium; 2012 Jul; 22(7):969-77. PubMed ID: 22750928
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and management of mineral and bone disorders in infants with CKD: clinical practice points from the ESPN CKD-MBD and Dialysis working groups and the Pediatric Renal Nutrition Taskforce.
Bacchetta J; Schmitt CP; Bakkaloglu SA; Cleghorn S; Leifheit-Nestler M; Prytula A; Ranchin B; Schön A; Stabouli S; Van de Walle J; Vidal E; Haffner D; Shroff R
Pediatr Nephrol; 2023 Sep; 38(9):3163-3181. PubMed ID: 36786859
[TBL] [Abstract][Full Text] [Related]
38. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
39. Review article: Addressing risk factors in chronic kidney disease mineral and bone disorder: can we influence patient-level outcomes?
O'Shea S; Johnson DW
Nephrology (Carlton); 2009 Jun; 14(4):416-27. PubMed ID: 19563384
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
